NCT03415776: TATH

Twice Against Thrice-weekly Hemodialysis

Terminated NA Last updated 28 October 2022

What this trial tests

NA trial testing Hemodialysis in Hemodialysis Complication in 208 participants. Terminated before completion.

Timeline

16 February 2018

Primary endpoint
25 October 2022

25 October 2022

Quick facts

Lead sponsor	Saint-Joseph University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	208
Start date	16 February 2018
Primary completion	25 October 2022
Estimated completion	25 October 2022
Sites	1 location across Lebanon

Drugs / interventions tested

• Hemodialysis

Conditions studied

• Hemodialysis Complication — all drugs for Hemodialysis Complication →

Sponsor

Saint-Joseph University

Who can join

Adults 18 to 95, any sex, with Hemodialysis Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hemodialysis is the most worldwide prescribed renal replacement therapy for patients with end-stage renal disease. The frequency of sessions per week remains a debatable issue. In the majority of developed Western and Asian countries, patients on chronic hemodialysis are undergoing three dialysis sessions weekly. In developing countries and some developed countries, a twice-weekly schedule independent of residual kidney function is still accepted, sometimes because of lack of resources and some other times because of patients' resistance to undergo three sessions per week. The primary objective of this trial is to assess the total mortality of patients on thrice against twice-weekly hemodialysis. The secondary objectives are a) to compare the rate of urgent supplementary hemodialysis sessions between the two arms, mainly those due to pulmonary edema and hyperkalemia, b) to compare the number of hospitalizations and duration of stay, c) to compare the rate of uncontrolled hypertension between the two groups, d) to analyze the quantity of erythropoiesis-stimulating agents (ESAs) in units to achieve a haemoglobin (Hb) 11 to 11.5 g/dl, e) to assess the factors associated with a higher mortality in the two groups.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Twice against thrice-weekly hemodialysis (TATH): a multicenter nonrandomized trial.
   Aoun M, Finianos S, Beaini C, Sleilaty G, et al · · 2025 · cited 1× · PMID 40188011 · DOI 10.1186/s12882-025-04105-3